A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-12. Anything still debated is marked as such rather than presented as settled.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
=== 1986 === 31 July Turbo: Once Around the Block, about British motor racing; the Ferrari F1/86 and the Imola Circuit in Emilia-Romagna in northern Italy, and Tifosi spectators; the 1984 British Grand Prix at Brands Hatch; the Motronic engine control units of Robert Bosch GmbH; Keith Duckworth, known for the Cosworth DFV, and Michael Kranefuss, head of Ford Motor Sport; Walter Hayes of Ford of Europe; Renault began turbocharged motor racing vehicles at the 1977 British Grand Prix on 16 July 1977, with the Renault RS01; Cosworth in Northampton; Beatrice Foods of the US, and Ford form an agreement in 1985, with Australian Alan Jones, with designer John Baldwin; the 1981 Italian Grand Prix and crash of John Watson; the assembled Cosworth GBA V6 engine is tested at Northampton. Produced by Patrick Uden, made by Uden Associates.
October 23, denoted 10/23 in the US, is recognized by some as Mole Day. It is an informal holiday in honor of the unit among chemists. The date is derived from the Avogadro number, which is approximately 6.022×1023. It starts at 6:02 a.m. and ends at 6:02 p.m. Alternatively, some chemists celebrate June 2 (06/02), June 22 (6/22), or 6 February (06.02), a reference to the 6.02 or 6.022 part of the constant.
== Pharmacology == Pegcetacoplan acts as a complement inhibitor, specifically targeting complement protein C3, which plays a crucial role in the pathogenesis of paroxysmal nocturnal hemoglobinuria. In individuals with paroxysmal nocturnal hemoglobinuria, there is a heightened and uninhibited complement activity, which may lead to intravascular (inside blood vessels) or extravascular (within the liver or spleen) hemolysis. By binding to and inhibiting C3, pegcetacoplan helps regulate complement activation, thereby reducing red blood cell destruction, anemia, blood clot formation, and improving bone marrow function. This targeted mechanism of action makes pegcetacoplan the first-in-class medication for the treatment of paroxysmal nocturnal hemoglobinuria, offering a promising therapeutic approach to address the underlying complement dysregulation in this condition.
21 February – The Government agreed a more targeted cost-of-living package, along with some universal payments, with €470m to be allocated for social protection measures. 22 February – Róisín Shortall and Catherine Murphy announced that they would stand down as co-leaders of the Social Democrats, with a successor to be appointed "at an early date." On 26 February, Holly Cairns was announced as the next leader of the party. 28 February – Minister for Education Norma Foley reversed a plan for Leaving Certificate candidates to sit Paper 1 of their English and Irish exams at the end of fifth year, after facing strong opposition from a number of organisations, including teacher and student representative bodies.
Changes in pH, surfactant concentration, and concentration of organic modifier play a significant role in determining the chromatographic separation. Often one or more of these parameters need to be optimized to achieve the desired separation, yet the optimum parameters must take all three variables into account simultaneously. The review by Garcia-Alvarez-Coque et al. mentioned several successful models for varying scenarios, a few of which will be mentioned here. The classic models by Armstrong and Nome and Foley are used to describe the general cases. Foley's model applies to many cases and has been experimentally verified for ionic, neutral, polar and nonpolar solutes; anionic, cationic, and non-ionic surfactants, and C8, C¬18, and cyano stationary phases. The model begins to deviate for highly and lowly retained solutes. Highly retained solutes may become irreversibly bound to the stationary phase, where lowly retained solutes may elute in the column void volume. Other models proposed by Arunyanart and Cline-Love and Rodgers and Khaledi describe the effect of pH on the retention of weak acids and bases. These authors derived equations relating pH and micellar concentration to retention. As the pH varies, sigmoidal behavior is observed for the retention of acidic and basic species. This model has been shown to accurately predict retention behavior. Still other models predict behavior in hybrid micellar systems using equations or modeling behavior based on controlled experimentation.
Sources: en.wikipedia.org
== Work == In 1934 Flory joined the Central Department of Dupont and Company working with Wallace H. Carothers. After Carothers' death in 1937, Flory worked for two years at the Basic Research Laboratory located in the University of Cincinnati. During World War II, there was a need for research to develop synthetic rubber, so Flory joined the Esso Laboratories of the Standard Oil Development Company. From 1943 to 1948 Flory worked in the polymer research team of the Goodyear Tire and Rubber Company. In 1948, Flory gave the George Fisher Baker lectures at Cornell University, and subsequently joined the university as a professor. In 1957, Flory and his family moved to Pittsburgh, Pennsylvania, where Flory was executive director of research at the Mellon Institute of Industrial Research. In 1961, he took up a professorship at Stanford University in the department of chemistry. After retirement, Flory remained active in the world of chemistry, running research labs both in Stanford, and IBM.
== Properties == Bromine is the third halogen, being a nonmetal in group 17 of the periodic table. Its properties are thus similar to those of fluorine, chlorine, and iodine, and tend to be intermediate between those of chlorine and iodine, the two neighbouring halogens. Bromine has the electron configuration [Ar]4s23d104p5, with the seven electrons in the fourth and outermost shell acting as its valence electrons. Like all halogens, it is thus one electron short of a full octet, and is hence a strong oxidising agent, reacting with many elements in order to complete its outer shell. Corresponding to periodic trends, it is intermediate in electronegativity between chlorine and iodine (F: 3.98, Cl: 3.16, Br: 2.96, I: 2.66), and is less reactive than chlorine and more reactive than iodine. It is also a weaker oxidising agent than chlorine, but a stronger one than iodine. Conversely, the bromide ion is a weaker reducing agent than iodide, but a stronger one than chloride. These similarities led to chlorine, bromine, and iodine together being classified as one of the original triads of Johann Wolfgang Döbereiner, whose work foreshadowed the periodic law for chemical elements. It is intermediate in atomic radius between chlorine and iodine, and this leads to many of its atomic properties being similarly intermediate in value between chlorine and iodine, such as first ionisation energy, electron affinity, enthalpy of dissociation of the X2 molecule (X = Cl, Br, I), ionic radius, and X–X bond length.
==== Adsorption ==== A straightforward method for reversible immobilization, involving the enzymes being adsorbed or attached physically onto a support substance. Adsorption can take place through weak non-specific forces, such as van der waals, hydrogen bonds, and hydrophobic interactions, whereas in ionic bonding the enzymes are bound through salt linkages. Adsorption on glass, alginate beads or matrix: Enzyme is attached to the outside of an inert material. In general, this method is the slowest among those listed here. As adsorption is not a chemical reaction, the active site of the immobilized enzyme may be blocked by the matrix or bead, greatly reducing the activity of the enzyme.
By choosing porous graphitic carbon as a stationary phase for liquid chromatography, even non derivatized glycans can be analyzed. Electrospray ionisation (ESI) is frequently used for this application.
=== N-degrons === Proteolytic cleavage can lead to exposure of residues at the N-terminus of a protein. According to the N-end rule, different N-terminal amino acids (or N-degrons) are recognized to a different extent by their appropriate ubiquitin ligase (N-recognin), influencing the half-life of the protein. For instance, positively charged (Arg, Lys, His) and bulky hydrophobic amino acids (Phe, Trp, Tyr, Leu, Ile) are recognized preferentially and thus considered destabilizing degrons since they allow faster degradation of their proteins.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.